Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cannon

Showing results (711-720 of 934) with videos related to

Pageof 94
Sort By:
BMJ (Clinical Research Ed.)|June 21, 2011
Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trialStefan K James, Matthew T Roe, Christopher P Cannon, et al.
Archives of Internal Medicine|October 29, 2003
Predictors of hospital mortality in the global registry of acute coronary eventsChristopher B Granger, Robert J Goldberg, Omar Dabbous, et al.
European Heart Journal|July 3, 2004
The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studiesDavid A Morrow, Elliott M Antman, Sabina A Murphy, et al.
American Journal of Hypertension|January 9, 2025
Continual Versus Occasional Blood Pressure (COOL-BP) in Remote Hypertension ManagementOzan Unlu, Christopher P Cannon, Simin Lee, et al.
Circulation|January 2, 2013
Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO StudyPayal Kohli, Lars Wallentin, Eric Reyes, et al.
The American Journal of Medicine|November 28, 2013
NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic diseasePayal Kohli, Ph Gabriel Steg, Christopher P Cannon, et al.
European Heart Journal|August 2, 2011
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomesRobert F Storey, Richard C Becker, Robert A Harrington, et al.
Lancet (London, England)|May 4, 2010
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies, Alexander Thompson, Pei Gao, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|April 17, 2014
Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE studyAntonio M Gotto, Uma Kher, Manash Shankar Chatterjee, et al.
European Journal of Heart Failure|June 27, 2024
Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trialMuthiah Vaduganathan, Christopher P Cannon, Meg J Jardine, et al.
Pageof 94

Showing results (711-720 of 934) with videos related to

Sort By:
Pageof 94
BMJ (Clinical Research Ed.)|June 21, 2011
Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trialStefan K James, Matthew T Roe, Christopher P Cannon, et al.
Archives of Internal Medicine|October 29, 2003
Predictors of hospital mortality in the global registry of acute coronary eventsChristopher B Granger, Robert J Goldberg, Omar Dabbous, et al.
European Heart Journal|July 3, 2004
The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studiesDavid A Morrow, Elliott M Antman, Sabina A Murphy, et al.
American Journal of Hypertension|January 9, 2025
Continual Versus Occasional Blood Pressure (COOL-BP) in Remote Hypertension ManagementOzan Unlu, Christopher P Cannon, Simin Lee, et al.
Circulation|January 2, 2013
Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO StudyPayal Kohli, Lars Wallentin, Eric Reyes, et al.
The American Journal of Medicine|November 28, 2013
NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic diseasePayal Kohli, Ph Gabriel Steg, Christopher P Cannon, et al.
European Heart Journal|August 2, 2011
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomesRobert F Storey, Richard C Becker, Robert A Harrington, et al.
Lancet (London, England)|May 4, 2010
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies, Alexander Thompson, Pei Gao, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|April 17, 2014
Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE studyAntonio M Gotto, Uma Kher, Manash Shankar Chatterjee, et al.
European Journal of Heart Failure|June 27, 2024
Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trialMuthiah Vaduganathan, Christopher P Cannon, Meg J Jardine, et al.
Pageof 94